100939-89-7

Usage

Uses

Used in Pharmaceutical Research and Development:
(3-METHOXY-PHENYL)-PIPERAZIN-1-YL-METHANONE is used as a research compound for its potential pharmacological properties, particularly in the exploration of its interaction with the central nervous system. It is valued for its contribution to the discovery and development of new pharmaceutical drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (3-METHOXY-PHENYL)-PIPERAZIN-1-YL-METHANONE is utilized for its psychoactive effects, which are of interest for the creation of novel therapeutic agents and the advancement of drug development strategies.
Used in Drug Development:
(3-METHOXY-PHENYL)-PIPERAZIN-1-YL-METHANONE is employed in drug development to investigate its potential as a precursor or component in the synthesis of new medications, especially those targeting the central nervous system and related disorders.

InChI:InChI=1/C12H16N2O2/c1-16-11-4-2-3-10(9-11)12(15)14-7-5-13-6-8-14/h2-4,9,13H,5-8H2,1H3

Upstream product

• 110-85-0 piperazine 
• 1711-05-3 m-anisoyl chloride 
• 2759-28-6 1-phenylmethylpiperazine 
• 586-38-9 3-Methoxybenzoic acid 
• 75560-62-2 N-(3-methoxybenzoyl)imidazole 
• 142-64-3 piperazine dihydrochloride 

Downstream Products

• 1593953-89-9 C₂₁H₂₀N₆O₂ 
• 1593954-26-7 C₂₀H₁₉N₇O₂ 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents

As a continuation to our previous research, twenty-eight aromatic-heterocyclic biphenyls were designed and synthesized as novel Bcr-Abl inhibitors. The title compounds were investigated for their antiproliferative activities against wild K562 cells and Imatinib-resistant K562 cells (K562R). The results indicated that most of them exhibited potent Bcr-Abl inhibition and moderate antiproliferative potency against K562 cells. Furthermore, three compounds 3, 7 and 21 displayed moderate antiproliferative activities against K562R cells. Molecular docking indicated that 3 bound more tightly with Bcr-AblT315I compared to Bcr-AblWT. The higher affinity was consistent with its relatively promising K562R cell growth inhibition. These aromatic-heterocyclic biphenyls could be considered as novel lead compound for optimized as Bcr-AblT315I inhibitors. They provide a good starting point for the further development of novel anti-leukemia agents capable of dealing with clinical acquired resistance against Imatinib.

Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms

We report the synthesis and biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeu

A Arylheterocycle chirality bcr - abl inhibitor and its preparation method and application

The invention discloses aromatic heterocyclic biphenyl Bcr-Abl inhibitors as well as a preparation method and application thereof. A structural formula of the inhibitors is shown in the specification, wherein in the structural formula, Ar is aromatic heterocycle; R is a mono-substituent or a di-substituent, and the substituent is alkyl or halogen. The series of inhibitors have a certain inhibiting effect on ABL1 kinase in vitro, can inhibit tumor cell proliferation and can be used for preparing antitumor drugs, especially CML (chronic myelocytic leukemia) drugs. The preparation method of the aromatic heterocyclic biphenyl Bcr-Abl inhibitors, which is provided by the invention, has the advantages of easiness in obtainment of raw materials, mild reaction conditions, simplicity in operation of reaction processes and cheap used reagents.

Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker

Forty-two compounds (series 8, 9 and 10) incorporated with diacylated piperazine have been synthesized and evaluated as novel Bcr-Abl inhibitors based on 'six-atom linker'. Five of them, 8d, 8h, 8l, 10m and 10p, displayed potent Bcr-Abl inhibitory activity comparable with Imatinib. Moreover, compounds 8e, 10q, 10s, and 10u were potent Bcr-Abl inhibitors with IC50 values at the sub-micromolecular level. Most compounds exhibited moderate to high antiproliferative activity against K562 cells. In particular, compound 9e was the most promising Bcr-Abl inhibitor. Docking studies revealed that the binding modes of these compounds were similar with Imatinib. These compounds could be considered as promising lead compounds for further optimization.

Reaction of piperazine with trimethylacetic arylcarboxylic anhydride; a convenient method for preparing monoacylated piperazine derivatives

A series of monosubstituted piperazine derivatives were obtained by the reaction of piperazine with trimethylacetic arylcarboxylic anhydrides in good yields, which were prepared in situ from arylcarboxylic acid with trimethylacetyl chloride in the presence of triethylamine.

Study of synthesis and cardiovascular activity of some furoxan derivatives as potential NO-donors

A series of hybrid molecules incorporating the furoxan and nicorandil moieties were designed as potential NO donors with cardiovascular and cerebrovascular activities. Thirty-six target molecules were successfully synthesized by conventional methods and characterized by infrared spectroscopy, 1H-NMR spectroscopy and high resolution mass spectra. The compounds were tested for their effects on KCl-induced contraction of rabbit thoracic aorta whose endothelium was denuded. Eight compounds were found to reduce KCl-induced contraction by more than 30% at 10 μM. All except one of these compounds are characterized by the presence of electron withdrawing groups in the phenyl ring attached via an amide or ester linkage to the furoxan moiety. The nature of the terminal carbonyl linkage (ester or amide) and the length or type of the alkyl chain bridging the two carbonyl functions have little effect on the activity. One of the active compounds, N-(4- methoxy-benzoyl)-N'-[3-methylfuroxanyl-4-carbonyl)piperazine (17i) was tested for hypotensive effects on anaesthetized rats at 1.5 mg/kg, and found to demonstrate a gradual and sustained hypotensive effect. The results suggest that the furoxannicorandil derivatives are a useful lead in the design of NO- donor compounds for hypertension.

Disubstituted piperazines

Piperazines of the formula STR1 and their salts, in which each of Ar1 and Ar2, independently of the other, represents phenyl that is unsubstituted or mono- or di-substituted by C1 -C7 -alkyl, C1 -C7 -alkoxy, cyano, halogen, trifluoromethyl, amino, C1 -C7 -alkylamino, di-C1 -C7 -alkylamino and/or by C1 -C7 -alkanoylamino, can be used as the active ingredients of medicaments and are manufactured in a manner known per se.